The quality assessment of the pharmacotherapy of patients with tuberculosis / HIV / AIDS co-infection according to the results of ABC / VEN / frequency analysis (research fragment)
DOI:
https://doi.org/10.24959/sphhcj.20.184Keywords:
co-infection TB / HIV / AIDS, antiretroviral therapy, clinical and economic analysis, frequency analysis, VEN analysis, ABC analysisAbstract
TB / HIV / AIDS co-infection is a long-term infectious disease of major medical and social importance associated with widespread, progressive damage to the immune system, risk of opportunistic infections, reduced quality of life for patients, high overall cost of treatment.
Aim. To determine the quality of pharmacotherapy of patients with TB / HIV / AIDS co-infection treated at a health institution (HI) in Mykolayiv according to the results of ABC / VEN / frequency analysis in order to assess the drug therapy compliance with the current standards and optimize costs for the pharmacotherapy of patients.
Materials and methods. The quality of the pharmacotherapy of patients was assessed using ABC, frequency and “formal” VEN-analyzes.
Results. Using the “formal” VEN analysis it was determined that most of the drugs prescribed were classified as vital since they were present in both medical and technological documents: State Formulary of Ukraine (SFU) of the 8th and 9th editions (75-83.3 % of drugs) and the current clinical protocol “Tuberculosis/HIV/AIDS” (88.9 % of drugs). According to the results of frequency analysis, leaders by prescription correspond to the main directions of treatment of patients with TB/HIV/AIDS co-infection. According to the results of ABC analysis, correction of the pharmacotherapy of patients is needed: the replacement of the high-cost original drug Atripla, which cost was 45.1 % of all funds for the treatment of patients, with its cheap generic analog to save public funds for the pharmacotherapy of patients.
Conclusions. The basic directions of the pharmacotherapy of patients with TB/HIV/AIDS co-infection in the HI of Mykolayiv correspond to the current clinical protocol for providing medical care to patients at the time of the study. The most prescriptions consist of drugs recommended by the clinical protocol and are available in the SPhU. In general, the pharmacotherapy of patients with TB / HIV / AIDS co-infection in the HI of Mykolayiv can be considered as rational from the clinical point of view. However, it has been also found that few patients (23 %) with co-morbidities received the appropriate treatment.References
Matiukha, L. F., Batsiura, H. V., Boiko, V. O. et al. (2015). Vedennia patsiienta z VIL-infektsiieiu/SNIDom simeinym likarem. Kyiv : Ahentstvo “Ukraina”.
Epidemichna sytuatsiia z VIL-infektsii v Ukraini stanom na 01.04.2019. Available at: https://phc.org.ua/kontrol-zakhvoryuvan/vilsnid/statistika-z-vilsnidu (Date of access: 20.05.2020).
Horiachyi, S. O., Holovchenko, I. Yu., Klymenko, O. V. (2012). Ukrainskyi khimioterapev-tychnyi zhurnal, 3 (27), 28-30.
MOZ Ukrainy (2019). Nakaz vid 05.06.2019 No. 1292 “Novyi klinichnyi protokol iz zastosuvannia antyretrovirusnykh preparativ dlia likuvannia ta profilaktyky VIL-infektsii”. Available at: https://moz.gov.ua/uploads/2/12794-dn_20190605_1292_dod.pdf (Date of access: 20.05.2020).
Ustinov, O. V. (2015). Ukrainskyi medychnyi chasopys, vypusk 22 travnia, 1-13.
Nakaz MOZU No. 1039 vid 31.12.2014 “Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Ko-infektsiia (Tuberkuloz/VIL-infektsiia/SNID)”. mtd.dec.gov.ua. Available at: http://mtd.dec.gov.ua/images/dodatki/2014_1039_Ko_VIL_SNID/2014_1039_YKPMD_Ko_VIL_SNID.pdf (Date of access: 20.05.2020).
Fediak, I. O., Kupnovytska, I. H., Hrynyk, N. R. (2018). Sotsialna farmatsiia v okhoroni zdorovia, 2, 19–27. doi: 10.24959/sphhcj.18.114.
Nemchenko, A .S., Kosiachenko, K. L., Korzh, Yu. V. (2012) Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 2 (22), 72-77.
Iakovlieva, L. V., Trystan, Y. V. (2017). Proceeding from Menedzhment ta marketynh u skladi suchasnoi ekonomiky, nauky, osvity, praktyky: zbirnyk naukovykh statei V Mizhnar. nauk.-prakt. Internet-konf., (30-31 bereznia 2017 roku) (рр. 96-108). Kharkiv: NFaU.
Derzhavnyi formuliar likarskykh zasobiv MOZ Ukrainy (vosmyi vypusk, 2016). Available at: http://www.dec.gov.ua/index.php/ua/111-golovna/1319-vosmij-vipusk-derzhavnogo-formulyara-likarskikh-zasobiv/ (Date of access: 20.05.2020).
Derzhavnyi formuliar likarskykh zasobiv MOZ Ukrainy (deviatyi vypusk, 2017). Available at: http://www.dec.gov.ua/index.php/ua/111-golovna/1319-devatij-vypusk-derzhavnogo-formulyara-likarskikh-zasobiv/ (Date of access: 20.05.2020).
Morozov, A. M., Iakovlieva, L. V., Bezditko et al. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno-profilaktychnomu zakladi (suprovid formuliarnoi systemy). Kharkiv: Styl-Yzdat.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
